news
AstraZeneca, Ionis heart drug fails in Phase 3
AstraZeneca and Ionis' investigational cardiovascular drug, an antisense oligonucleotide, failed to meet its primary endpoint in a Phase 3 trial. The drug aimed to reduce the risk of major adverse cardiovascular events in patients with high triglycerides and established cardiovascular disease. The unexpected failure has implications for similar RNA-based therapies in development.
AstraZeneca and Ionis' investigational cardiovascular drug, an antisense oligonucleotide, failed to meet its primary endpoint in a Phase 3 trial. The drug aimed to reduce the risk of major adverse cardiovascular events in patients with high triglycerides and established cardiovascular disease. The unexpected failure has implications for similar RNA-based therapies in development.
The architecture take
So, a major drug targeting heart disease, one of those new-gen RNA therapies, just tanked its Phase 3 trial. The idea was to quiet certain genes that make a protein linked to high triglycerides, which then links to heart trouble. It worked in earlier phases, which is why this failure hits hard. They called it 'unexpected,' and that's the kicker for the biotech world. The drug was meant to lower lipid levels, but it didn't translate into fewer heart attacks or strokes for patients already at risk. For us, this is a reminder that even when the mechanism makes sense on paper – 'silencing' a gene to fix a problem – the body's entire system is far more complex. You can tweak one knob, but the whole orchestra doesn't necessarily play in tune. It means researchers need to look beyond just lowering a biomarker and really track how that impacts the whole cardiovascular load.